Ohio Medicaid spending on GLP-1 drugs

How much did Ohio Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $407.0 million for GLP-1 drugs paid through Ohio Medicaid in 2025, across at least 425,347 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 115 rows of 357, so these figures are floors.

Pharmacies were reimbursed at least $88.5 million for GLP-1 drugs paid through Ohio Medicaid in 2026 (quarter 1 only, as posted so far), across at least 90,654 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 26 rows of 96, so these figures are floors.

By year and ingredient

2020at least $11,271,758No dataat least $42,952,433at least $68,865,438at least $3,577,716at least $65,773at least $829,692at least $213,219at least $127,776,029
2021at least $14,935,945No dataat least $40,061,165at least $118,048,243at least $1,717,865at least $11,946at least $678,725$198,672at least $175,652,561
2022at least $28,557,597at least $5,305,319at least $37,559,088at least $185,165,979at least $1,238,662Suppressedat least $555,896$168,345at least $258,550,885
2023at least $48,147,487at least $33,005,182at least $35,073,470at least $248,513,074at least $1,242,013No dataat least $480,799at least $168,519at least $366,630,545
2024at least $37,695,889at least $27,612,957at least $17,082,821at least $262,113,555at least $1,410,815No dataat least $287,531at least $50,007at least $346,253,575
2025at least $28,399,648at least $29,543,280at least $6,194,208at least $342,355,815at least $297,241No data$153,454at least $11,188at least $406,954,834
2026 (Q1)at least $7,713,865at least $9,981,924at least $1,268,003at least $69,472,365at least $26,466No dataat least $19,529Suppressedat least $88,482,152

By product, 2025

Ozempicat least $16,995,782at least 17,5424 of 28
Rybelsusat least $1,188,879at least 1,1979 of 25
Wegovyat least $10,214,988at least 7,78010 of 41
Mounjaroat least $26,368,761at least 25,19318 of 65
Zepboundat least $3,174,520at least 2,99222 of 40
Liraglutide (generic name listing)at least $1,982,784at least 4,29214 of 47
Saxendaat least $72,944at least 624 of 7
Victoza$4,138,4806,6220 of 16
Trulicityat least $342,355,815at least 359,09320 of 62
Bydureonat least $20,903at least 262 of 3
Byettaat least $209,568at least 2556 of 9
Exenatide (generic name listing)at least $66,770at least 893 of 6
Soliqua$153,4541920 of 4
Xultophyat least $11,188at least 123 of 4

By quarter, 2025

Q1 2025at least $94,550,584at least 99,58229 of 83
Q2 2025at least $102,322,010at least 106,98030 of 90
Q3 2025at least $104,821,056at least 109,43627 of 89
Q4 2025at least $105,261,184at least 109,34929 of 95

By quarter, 2026 (posted so far)

Q1 2026at least $88,482,152at least 90,65426 of 96

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.